MCX Shares at ₹2,970.80: UBS Signals More Upside After Fresh Upgrade

MCX shares are trading at ₹2,970.80 after UBS upgraded the stock to Buy from Neutral on August 12, 2026. The brokerage raised its price target to ₹3,800 from ₹3,600, citing strong Q1FY27 earnings, favorable regulation, and steady trading volumes. The upgrade reverses UBS’s own downgrade from May 29, 2026, when it flagged concerns over peak earnings momentum.

Why UBS Turned Bullish On MCX Shares Again

UBS analyst Lavanya Tottala pointed to resilient trading volumes and improving valuation comfort as key reasons behind the upgrade. The brokerage now sees MCX shares trading at a discount worth buying into.

• MCX valuation: 40 times 1-year forward earnings, per UBS estimates.
• Discount cited: roughly 15% below MCX’s own three-year average valuation.
• New target: ₹3,800, up from ₹3,600 previously.
• Implied upside from ₹2,970.80: approximately 27.9%.

UBS’s about-turn stands out given how sharply it reversed course within just three months. That May downgrade had triggered a 5% single-day drop in MCX shares, making this upgrade a notable sentiment shift for the stock.

UBS Turns Bullish On MCX India & Nuvama Wealth #MCX: Target at Rs 3,800, valuation at 15% discount to 3-yr avg #Nuvama Wealth: Target at Rs 2,095; Riding India's financialisation of savings
Strong earnings growth the common thread @MCXIndialtd & @Nuvama_Wealth @YashJain88… pic.twitter.com/bETQIX49jA

— CNBC-TV18 (@CNBCTV18News) August 13, 2026

How MCX Shares Have Performed In 2026

MCX shares have significantly outpaced the broader Indian market this year, even after some sharp swings tied to earlier analyst downgrades. That relative strength has caught the attention of multiple brokerages beyond UBS alone.

• 2026 year-to-date gain: 34%, compared with an 8.7% drop in the Sensex.
• 52-week high: ₹3,480; 52-week low: ₹1,460.80.
• Market capitalization: approximately ₹70,359.9 crore as of August 11.
• Mutual fund shareholding: 30.07% as of August 11, 2026.

That scale of outperformance against a falling Sensex highlights just how differently investors are treating MCX compared to the broader market this year.

What’s Driving MCX’s Volume Growth and Regulatory Tailwinds

A fresh SEBI proposal to allow foreign portfolio investors into non-cash-settled, non-agricultural commodity derivatives triggered a 3% jump in MCX shares this week. Analysts at Jefferies and Morgan Stanley both flagged the move as structurally positive.

• FPI participation in cash-settled commodity F&O currently stands at 5% to 6%, according to Jefferies.
• Estimated PAT boost from similar FPI participation: roughly 3%, per Jefferies analyst Supratim Datta.
• Additional potential upside: Bulldex and Metldex options could add 10% to PAT within three years.
• Condition for that upside: index options reaching 10% of monthly equity ADTO.

Peers reacting to the same regulatory news included BSE Ltd, CDSL, and Indian Energy Exchange, all part of India’s listed exchange ecosystem competing for similar derivatives volume growth.

MCX’s Q1FY27 Earnings Backing The Upgrade

MCX’s June 2026 quarterly results gave UBS concrete numbers to justify its renewed bullish stance. Both revenue and profit growth accelerated sharply compared to the prior fiscal year.

• Q1FY27 EPS: ₹16.21 for the quarter ended June 30, 2026.
• FY26 full-year EPS: ₹52.22, more than double FY25’s comparable figure.
• FY26 revenue: ₹2,429 crore, up 102.95% year-over-year.
• FY26 earnings: ₹1,332 crore, up 137.76% year-over-year.

That earnings acceleration gives UBS’s ₹3,800 target real fundamental backing, rather than resting on sentiment alone. Bloomberg’s broader analyst consensus target stood at ₹3,304 before this latest UBS revision, implying the brokerage community may still be catching up to UBS’s newest estimate.

Bottom Line

UBS’s swing from downgrade to upgrade within three months shows just how quickly sentiment around MCX shares can shift. With a ₹3,800 target, strong Q1FY27 earnings, and a favorable SEBI proposal now in play, the stock has multiple catalysts working in its favor heading into the rest of FY27.

Disclaimer:

The content shared by Meyka AI PTY LTD is for research and informational purposes only. Meyka is not a financial advisory service, and the information provided should not be treated as investment or trading advice.